Current Strategy for Implementing Advanced Tech to Address Multidrug Resistant Bacteria
TL;DR
These technologies offer promising alternatives to failing antibiotics, especially against pathogens with complex resistance mechanisms, however, limitations include toxicity concerns, immunological variability, immunological variability, lack of clinical validation, and cost barriers.
Abstract
This review explores emerging technological strategies aimed at combating Multidrug-Resistant Bacteria (MDRB), including MRSA, CRE, and VRE. These pathogens pose a critical public health threat due to rising resistance to conventional antibiotics. The study synthesizes findings on advanced approaches like nanotechnology, host-directed therapies, novel antimicrobials, combination regimens, and phytochemicals. A comprehensive literature review was performed using databases such as PubMed, Scopus, Web of Science, and Google Scholar, with keywords including “nanoparticles,” “hostdirected therapy,” and “phytochemicals.” Inclusion criteria prioritized peer-reviewed studies on antimicrobial interventions for MDRB. Data were grouped thematically and analyzed narratively to identify effective technologies and existing research gaps. Nanoparticles (e.g., AgNPs, ZnO NPs) showed antibacterial effects via membrane disruption and reactive oxygen species generation. Host-directed therapies, like cytokine modulators and immune checkpoint inhibitors, improved bacterial clearance. New antibiotics such as Cefiderocol and Eravacycline effectively targeted resistant Gram-negative strains. Combination therapies improved antibiotic efficacy, especially against biofilm-forming bacteria. Phytochemicals such as gingerol enhanced antibiotic activity and disrupted resistance mechanisms. These technologies offer promising alternatives to failing antibiotics, especially against pathogens with complex resistance mechanisms. However, limitations include toxicity concerns (nanoparticles), immunological variability (host therapies), lack of clinical validation, and cost barriers. Integration into clinical practice remains limited by regulatory and logistical challenges. Advanced therapeutic strategies hold strong potential for addressing MDRB. However, successful clinical translation requires further research, global cooperation, and investment in regulatory infrastructure.
